Bio-Techne Corporation (BIT:1TECH)
Italy · Delayed Price · Currency is EUR | Market Cap | 10.12B +27.1% |
| Revenue (ttm) | 1.06B -0.4% |
| Net Income | 159.16M +147.8% |
| EPS | 1.02 +152.2% |
| Shares Out | n/a |
| PE Ratio | 63.56 |
| Forward PE | 36.79 |
| Dividend | 0.27 (0.43%) |
| Ex-Dividend Date | Aug 21, 2026 |
| Volume | n/a |
| Open | 64.26 |
| Previous Close | 64.34 |
| Day's Range | 64.26 - 64.26 |
| 52-Week Range | 37.97 - 67.98 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 30, 2026 |
About Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, a... [Read more]
Financial Performance
In fiscal year 2026, Bio-Techne's revenue was $1.22 billion, a decrease of -0.38% compared to the previous year's $1.22 billion. Earnings were $181.84 million, an increase of 147.86%.
Financial numbers in USD Financial StatementsNews
Bio-Techne expands global GMP manufacturing network with new Bristol facility
Bio-Techne (TECH) announced the opening of a new manufacturing facility for Good Manufacturing Practice – GMP – grade small molecules in Bristol, U.K. The purpose-built 10,000-square-foot Bristol faci...
Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development
Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applications New Bristol facility expands GMP small molecule production capacity and complements recent inv...
Bio-Techne shareholders approve acquisition by Merck KGaA
Bio-Techne (TECH) announced that shareholders voted to approve and adopt the definitive agreement under which Merck KGaA (MKGAY), Darmstadt, Germany proposes to acquire Bio-Techne at a Special Meeting...
Bio-Techne’s shareholders approve acquisition by Merck KGaA
Bio-Techne (TECH) announced that shareholders voted to approve and adopt the definitive agreement under which Merck, Darmstadt, Germany proposes to acquire Bio-Techne at a Special Meeting of Sharehold...
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne s...
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise Regional hub will support researchers and organizations across the DACH and broader EMEA r...
Bio-Techne Proxy statement: Proxy filing
Bio-Techne filed a proxy statement on September 14, 2026, providing details for shareholder voting and corporate governance matters.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)
BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
Bio-Techne Proxy statement: Proxy filing
Bio-Techne filed a proxy statement on September 9, 2026, providing details for shareholder voting and corporate governance matters.
Bio-Techne Proxy statement: Proxy filing
Bio-Techne filed a proxy statement on September 2, 2026, providing details for shareholder voting and corporate governance matters.
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
Fiscal 2026 highlights: Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets Market-based Scope 1 and 2 emissions reduced 49% year-over-year More t...
Bio-Techne Proxy statement: Proxy filing
Bio-Techne filed a proxy statement on August 25, 2026, providing details for shareholder voting and corporate governance matters.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)
BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Bio-Techne Proxy statement: Proxy filing
Bio-Techne filed a proxy statement on August 20, 2026, providing details for shareholder voting and corporate governance matters.
Bio-Techne reports Q4 adjusted EPS 52c, consensus 52c
Reports Q4 revenue $321.2M, consensus $314.52M. “Bio-Techne (TECH) ended fiscal 2026 with improved performance and solid execution across the business, reflecting the value our differentiated solution...
Bio-Techne downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo downgraded Bio-Techne (TECH) to Equal Weight from Overweight with a $73 price target
Wells downgrades Bio-Techne on pending Merck KGaA buyout
Wells Fargo downgraded Bio-Techne (TECH) to Equal Weight from Overweight with a price target of $73, up from $62. The company posted a solid quarter but commentary was limited given…
Bio-Techne Corrects Dividend Announcement
MINNEAPOLIS, Aug. 13, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is issuing a correction to its dividend announcement released yesterday. The initial version incorrectly stated the sha...
Bio-Techne beats revenue estimates on research, diagnostics demand uptick
Bio-Techne beat Wall Street estimates for fourth-quarter revenue on Wednesday helped by growth in its research and diagnostics businesses.
Bio-Techne Releases Fourth Quarter Fiscal 2026 Results
MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026. Fourth Quarter FY2026 Highlights Four...
Bio-Techne Declares Dividend
MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2...
Bio-Techne Earnings release: Q4 2026
Bio-Techne released its Q4 2026 earnings on August 12, 2026, summarizing the period's financial results.
Bio-Techne Annual report: Q4 2026
Bio-Techne has published its Q4 2026 annual report on August 12, 2026.
Bio-Techne Proxy statement: Proxy filing
Bio-Techne filed a proxy statement on August 10, 2026, providing details for shareholder voting and corporate governance matters.
Bio-Techne Proxy statement: Proxy filing
Bio-Techne filed a proxy statement on July 9, 2026, providing details for shareholder voting and corporate governance matters.